Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: A multinational, randomised, double-blind study

Current Medical Research and Opinion

Volumn 15, Issue 3, 1999, Pages 228-240

  Ose, Leiv ^a   Luurila, Olavi ^b   Eriksson, J ^c   Olsson, Anders ^d   Lithell, Hans ^e   Widgren, Bengt ^f  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Lääkäriasema Koe Oy   (Finland)

^c Health Centre of Seinäjoki   (Finland)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cerivastatin; Efficacy; Hypercholesterolaemia; Safety

Indexed keywords

CERIVASTATIN; CHOLESTEROL; CREATINE KINASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DYSURIA; FEMALE; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERCHOLESTEROLEMIA; IMPOTENCE; INSOMNIA; JOINT STIFFNESS; LETHARGY; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RASH; SEX DIFFERENCE; SIDE EFFECT; SINUSITIS; TRIACYLGLYCEROL BLOOD LEVEL; VISUAL IMPAIRMENT;

EID: 0032842577     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007999909114095     Document Type: Article

References (14)

1. Casteli, W. P. (1984). Epidemiology of coronary heart disease: the Framingham study. Am. J. Med., 76, 4-12.
2. LaRosa, J. C., Hunninghake, D., Bush, D., et al. (1990). The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol and coronary heart disease: a joint statement by the American Heart Association and the National Heart, Lung and Blood Institute. Circulation, 81, 1721-1733.
3. Martin, M. J., Hulley, S. B., Browner, W. S., et al. (1986). Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet, ii, 933-936.
4. Scandinavian Simvastatin Survival Study Group (1994). Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383-1389.
5. Shepherd, J., Cobbe, S. M., Ford, I., et al. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N. Engl. J. Med., 333, 1301-1307.
6. Sacks, F. M., Pfefer, M. A., Moye, L. A., et al. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med., 335, 1001-1009.
7. Stein, E. A., Schopen, U., Catagay, M., et al. (1999). Cerivastatin (0.1-0.4 mg/day) versus placebo: a pooled efficacy analysis. 71st European Atherosclerosis Society (EAS) Congress. Athens, Greece, 26-29 May 1999 (abstract accepted). Atherosclerosis, 144, 35.
8. Mück, W. (1998). Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs, 56 (Suppl 1), 15-23.
9. Geil, P. B., Anderson, J. W., Gustafson, N. J. (1995). Women and men with hypercholesterolemia respond similarly to an American Heart Association Step I Diet. J. Am. Dietet. Ass., 95, 436-446.
10. Betteridge, D. J. (1999). International multicentre comparison of cerivastatin with placebo and simvastatin for the treatment of patients with primary hypercholesterolaemia. Int. J. Clin. Pract., 53, in press.
11. Roberts, W. C. (1997). The rule of 5 and the rule of 7 in lipid-lowering by statin drugs (editorial). Am. J. Cardiol., 80, 106-107.
12. Shepherd, J., Cobbe, M., Ford, I., et al. for the West of Scotland Coronary Prevention Study Group (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N. Engl. J. Med., 333, 1301-1307.
13. Sacks, F. M., Pfeffer, M. A., Moye, L. A., et al. for the Cholesterol and Recurrent Events Trial Investigators (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med., 335, 1001-1009.
14. Downs, J. R., Clearfield, M., Weis, S., et al. for the AFCAPS/TexCAPS Research Group (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA, 279, 1615-1622.